AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?
AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.
Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.
In phase 3 trials, Alkermes' ALKS-5461 shows promise for the treatment of depression.
In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.
MannKind may be on the precipice of growth surge thanks to Afrezza, but these three biotech stocks are still growing faster than MannKind.
These 10 stocks were the top large-cap performers in healthcare during 2014.
There's more to top dividend-paying stocks than the yield.
Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?
Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.